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The vastmajority of coding variants are rare, and assessment of the contribution of rare variants to complex traits is hampered by low sta-
tistical power and limited functional data. Improvedmethods for predicting the pathogenicity of rare coding variants are needed to facil-
itate the discovery of disease variants from exome sequencing studies. We developed REVEL (rare exome variant ensemble learner), an
ensemble method for predicting the pathogenicity of missense variants on the basis of individual tools: MutPred, FATHMM, VEST, Poly-
Phen, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP, SiPhy, phyloP, and phastCons. REVEL was trained with recently
discovered pathogenic and rare neutral missense variants, excluding those previously used to train its constituent tools. When applied
to two independent test sets, REVEL had the best overall performance (p< 1012) as compared to any individual tool and seven ensemble
methods: MetaSVM, MetaLR, KGGSeq, Condel, CADD, DANN, and Eigen. Importantly, REVEL also had the best performance for distin-
guishing pathogenic from rare neutral variants with allele frequencies <0.5%. The area under the receiver operating characteristic curve
(AUC) for REVELwas 0.046–0.182higher in an independent test set of 935 recent SwissVar disease variants and123,935putativelyneutral
exome sequencing variants and 0.027–0.143 higher in an independent test set of 1,953 pathogenic and 2,406 benign variants recently
reported in ClinVar than the AUCs for other ensemblemethods.We provide pre-computed REVEL scores for all possible humanmissense
variants to facilitate the identification of pathogenic variants in the sea of rare variants discovered as sequencing studies expand in scale.Introduction
Interpreting genetic variation from next-generation seq-
uencing (NGS) datasets is essential for the advancement
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to the missing heritability from genome-wide association
studies.5,6 However, the majority of nonsynonymous var-
iants discovered by NGS have unknown significance
because experimental validation of large numbers of
rare variants is infeasible, and association studies require
prohibitively large sample sizes to detect rare variants
with modest effect sizes with high statistical power.
Therefore, computational tools that can accurately pre-
dict the pathogenicity of rare variants are needed to
help identify those variants that are most likely to cause
disease.
Many tools for predicting the pathogenicity of missense
variants have been developed based on features such as
amino acid or nucleotide conservation and biochemical
properties of the amino acid substitutions.7–18 However,
individual tools often disagree, in part because they utilize
different predictive features. Ensemble methods that
combine the results of multiple individual predictors
can improve performance.19–28 However, few existing
pathogenicity prediction tools have targeted the interpre-
tation of rare variants.24 Current tools are often trained
on predominantly common neutral variants and some
explicitly impose a minimum AF threshold for defining
neutral training variants.15,21,25 In contrast, most disease
training variants are rare. As a result of this AF imbalance
between disease and neutral training variants, tools that
rely on AF as a predictive feature might have a lower
ability to distinguish disease variants from rare neutral
variants than from common ones.24 Biological differences
such as higher conservation scores for rare versus com-
mon variants might also make rare neutral variants
more difficult to distinguish from disease variants.24,29
Despite the fact that the vast majority of nonsynonymous
variants discovered by NGS are rare, the performance of
existing prediction tools on rare variants is not well
known.30 Thus, there is a growing need for the develop-
ment and evaluation of tools for predicting the pathoge-
nicity of rare variants.
Here, we present an ensemble method for predicting
the pathogenicity of missense variants that outper-
forms existing approaches overall and when applied
to rare variants. The rare exome variant ensemble
learner (REVEL) method incorporates recently devel-
oped individual prediction tools as features and was
trained on recently discovered disease and rare neutral
missense variants that did not overlap with the training
data for its constituent predictors. We also assembled
two large independent test sets of recently discovered
pathogenic and benign variants that parallel the likely
application of REVEL to newly discovered variants
from NGS studies. We benchmark the performance of
REVEL and existing ensemble predictors for distin-
guishing disease mutations from neutral variants
across a broad range of AFs. To make our method
easily accessible for research and clinical use, we pro-
vide pre-computed REVEL scores for all possible human
missense variants.31878 The American Journal of Human Genetics 99, 877–885, OctoberMaterial and Methods
Random Forest
We trained a random forest on the set of variants described below
by using the R ‘‘randomForest’’ package32 with 1,000 binary
classification trees.33,34 We selected the number of trees to be
sufficiently large for the out-of-bag (OOB) error rate to plateau;
sensitivity analyses showed that increasing the number of trees
to 3,000 did not improve performance on the training dataset.
The OOB prediction for a given training variant is the proportion
of trees that classified the variant as pathogenic across only those
trees in the forest that excluded the variant from their bootstrap-
ped training sample.33 Four features were selected at random as
candidates for each split in the random forest trees, which was
the default value for 18 features described below. To address the
imbalance in the numbers of available disease and neutral training
variants, we sampled the same number (n ¼ 6,182) of disease and
neutral variants when generating the bootstrapped training set for
each tree in the forest. The importance of each predictive feature
was measured by the total decrease in the Gini index33 (improve-
ment in node purity) for all splits on that feature, averaged over all
trees in the forest.Training Variants
REVEL was trained with putative rare neutral and disease
missense variants. Disease variants were obtained from the
Human Gene Mutation Database (HGMD)35 version 2015.2 and
were restricted to the set of missense disease mutations (DMs)
added to HGMD since August 1, 2012 to minimize overlap with
variants previously used to train component features in the
REVEL random forest. Missense exome sequencing variants
(ESVs) were obtained from the Exome Sequencing Project (ESP)4
European-American and African-American populations, the
Atherosclerosis Risk in Communities (ARIC) study36 European-
American and African American populations, and the 1000
Genomes Project (KGP)3 European, Yoruban, and Asian popula-
tions, as recorded in dbNSFP31 version 2.7. After excluding all
disease variants in HGMD and the data sources for test sets 1
and 2 described below, the remaining missense ESVs were
considered putatively neutral. For both the disease and neutral
training variants, we also excluded all variants that had previ-
ously been used to train individual component features in the
REVEL random forest; specifically, MutPred,8 PolyPhen-2,10
MutationTaster,11 FATHMM v2.3,14 and VEST 3.0.15 Finally,
when a given genetic variant corresponded to multiple amino
acid substitutions (AASs) at the protein level, only one AAS was
selected at random. After applying all exclusion criteria, a total
of 6,182 disease variants and 281,972 putatively neutral ESVs re-
mained. We randomly selected approximately half (n ¼ 140,921)
of the putatively neutral ESVs, of which 123,706 rare ESVs (with a
maximum alternate AF between 0.1% and 1% across the seven
study populations) were used for training, and 17,215 ESVs
with an AF >1% were used for initial evaluation of performance
across a range of AFs. The remaining half of ESVs were held out
for use as independent test variants as described below. Thus,
the final training set consisted of 6,182 HGMD disease variants
and 123,706 rare neutral ESVs.Features
REVEL incorporates a total of 18 individual pathogenicity predic-
tion scores from 13 tools as predictive features. MutPred scores6, 2016
were newly computed for this study with the UniProt37 canonical
protein sequence when available and the Ensembl38 canonical
transcript otherwise. PROVEAN13 scores were obtained from
dbNSFP v2.9 (February 3, 2015). 16 additional scores were obtained
fromdbNSFP v2.7 (September 12, 2014), including eight functional
prediction scores (SIFT,7 PolyPhen-2 HVAR and HDIV, LRT,9
MutationTaster, MutationAssessor,12 FATHMM v2.3, and VEST
3.0) and eight conservation scores (GERPþþ,39 SiPhy,40 three
phyloP41 scores for primates, placental mammals, and vertebrates,
and three phastCons42 scores for primates, placental mammals,
and vertebrates). For PolyPhen-2, FATHMM, and PROVEAN, when
multiple protein isoforms were associated with a given variant, we
used the average score across all isoforms. Missing features were
imputed with the k-nearest neighbors method implemented in
the R ‘‘impute’’ package.43Missing feature values for a given variant
were assigned the average value of the non-missing values of that
feature from its k ¼ 40 nearest neighboring variants; when more
than 50% of features were missing for a given variant, we assigned
to each missing feature its overall mean across all variants.Test Sets
We assembled two independent test sets that did not overlap with
either the REVEL training data or the training data for the compo-
nent features of REVEL. Test set 1 consisted of 935 disease variants
added to SwissVar44 (release 2015_10) since August 1, 2012 and
approximately half (n ¼ 141,051) of the putatively neutral
missense ESVs described above that had not been included in
the REVEL training set or initial evaluation. Test set 2 consisted
of 1,953 pathogenic or likely pathogenic and 2,406 benign or
likely benign variants recently deposited into ClinVar45,46 by sub-
mitters following variant classification guidelines similar to the
American College of Medical Genetics and Genomics (ACMG)
guidelines.47,48 Specifically, all single-nucleotide missense variants
submitted to ClinVar by GeneDx, Emory Genetics Laboratory,
Partners HealthCare Laboratory for Molecular Medicine,49 Univer-
sity of Chicago Genetic Services Laboratory, Ambry Genetics, and
Invitae were downloaded on October 13, 2015. We excluded the
following from both test sets 1 and 2: all REVEL training variants,
all DM variants added to HGMD prior to August 1, 2012, and all
variants that had previously been used to train individual compo-
nent features in REVEL. Finally, to eliminate overlap between the
two test sets, we excluded any variants that were present in both
SwissVar and ClinVar from test set 1 if benign (n ¼ 9) and from
test set 2 if pathogenic (n ¼ 12).Comparators
We compared the performance of REVEL to seven ensemble pre-
diction tools that were recently developed, widely used, and
readily implemented: MetaLR,28 MetaSVM,28 Eigen,50 CADD16
v1.3, DANN,17 Condel,19 and KGGSeq23,24 v0.8. We ran KGGSeq
with the default model selection option that chooses an optimized
set of features for each variant.24 We plotted receiver operating
characteristic (ROC) curves and compared the area under the
ROC curve (AUC) estimates for different tools by using Delong’s
test51 implemented in the R ‘‘pROC’’ package.52We also computed
the area under the precision-recall (PR) curve by using the R
‘‘ROCR’’ package.53 For the training variants, REVEL scores were
computed by using only the OOB predictions, which have been
shown to provide performance estimates that are as accurate as
for an independent test set of equal size consisting of variants
with similar characteristics.33The AmericResults
Characterization of REVEL Features
The REVEL ensemble score combines pathogenicity pre-
dictions from 18 individual scores (features), including 8
conservation scores and 10 functional scores. Figure 1A
shows the correlation among individual features. The con-
servation scores, as well as LRT and Mutation Taster, were
almost all highly (Spearman rank correlation coefficient,
R> 0.6) to moderately correlated (0.4< R< 0.6). Five func-
tional scores (MutationAssessor, PROVEAN, VEST, and
PolyPhen-2 HDIV and HVAR) were almost all highly
correlated. VEST was also highly correlated with several
conservation scores, LRT, and MutationTaster. In contrast,
FATHMM had low correlation (R < 0.4) with all other
scores, and MutPred and SIFT had low to moderate correla-
tion with other scores. The five most important features in
the REVEL random forest were FATHMM, VEST, Mutation-
Assessor, MutPred, and PolyPhen-2 HVAR (Figure 1B). The
importancemeasure for an individual feature reflects corre-
lations with other features as well as its intrinsic predictive
ability because importance may be shared among corre-
lated features.34Overall Performance of REVEL as Compared with
Other Methods
The REVEL ensemble score discriminated well between
HGMD disease mutations and putatively neutral ESVs,
and an overall AUC of 0.908 was estimated with OOB pre-
dictions for the training set (Figure 2A). The AUC for
REVEL was significantly better than any of its constituent
features (maximum p < 1012 for any pairwise compari-
son), among which VEST (AUC ¼ 0.844) and FATHMM
(AUC ¼ 0.824) had the highest AUCs (Table S1). AUCs
for the other individual prediction tools ranged from
0.589 to 0.809 and tended to be higher for functional pre-
dictors (0.717–0.844) than for conservation scores (0.589–
0.791). The AUC for REVEL was also significantly better
than the other ensemble methods (maximum p < 1012
for any pairwise comparison), among which MetaLR
(AUC ¼ 0.883) and MetaSVM (AUC ¼ 0.879) had the
next highest AUCs (Figure 2A; Table S2).Performance for Rare versus Common Neutral
Variants
We next compared the performance of REVEL to that of
other ensemble methods for discriminating between
HGMD disease mutations, which are predominantly rare,
and putatively neutral ESVs with AFs ranging from very
rare (0.1%–0.3%) to common (>5%). We found that all
of the ensemble methods tended to have a worse ability
to discriminate disease mutations from rare neutral vari-
ants than from common neutral variants (Figure 2B; Table
S2). However, compared to other ensemble methods,
REVEL had superior discriminatory ability for neutral vari-
ants within all AF ranges up to 3%, with the greatestan Journal of Human Genetics 99, 877–885, October 6, 2016 879
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Figure 1. Individual Prediction Tools Included as Features in the REVEL Random Forest
(A) Correlation among the individual features, ordered by hierarchical clustering. The heatmap illustrates the Spearman rank correlation
coefficients between features computed for the REVEL training variants.
(B) Relative importance of individual features. Gini importance estimates were normalized to sum to one.improvements in AUC for rare variants with AF < 0.5%
(Figure 2B; Table S2). For neutral variants with AF > 3%,
REVEL had the second highest AUC after MetaLR. In
addition, the performance of REVEL appeared to be
less sensitive to neutral variant AF than other methods.
The AUC range for very rare to common variants was nar-
rowest for REVEL (0.897–0.957) and widest for DANN
(0.703–0.897), which appeared to be most sensitive to AF
(Table S2).
Performance Evaluation in Two Independent Test Sets
In test set 1, consisting of 935 independent disease muta-
tions from SwissVar and 141,051 putatively neutral ESVs,
the relative performance of all eight ensemble predictors
(Figure 3; Table S3) was similar to that observed in the
training set. REVEL had the best performance both overall
(p< 1012) and for neutral variants within all AF ranges up
to 5%. For common neutral variants with AF > 5%, REVEL
was again surpassed only by MetaLR. The improvement in
AUC obtained with REVEL versus with the other ensemble
methods was again greatest for rare neutral variants. In test
set 2, consisting of 1,953 pathogenic and 2,406 benign var-
iants from ClinVar, we confirmed that REVEL had the best
performance among the ensemble methods both overall
(p < 1012) and for neutral variants within all AF ranges
up to 3% and that the improvement in AUC was greatest
for rare neutral variants (Figure 4; Table S4). All of the
ensemble methods had a better overall ability to distin-
guish benign versus pathogenic variants from ClinVar
than putatively neutral ESVs versus disease variants from880 The American Journal of Human Genetics 99, 877–885, OctoberSwissVar or HGMD, which could be a consequence of the
more stringent definition of benign variants from ClinVar.
REVEL also had the best overall performance measured by
the area under the PR curve (Table S5) across a wide range
of proportions of disease variants represented in the
training set (4.8%) and test sets 1 (0.7%) and 2 (44.8%).
Interpretation of REVEL Scores
The REVEL score for an individual variant can range from
zero to one, reflecting the proportion of trees in the
random forest that classified the variant as pathogenic.
REVEL score distributions for the 6,182 HGMD disease
and 123,706 putatively neutral ESV training variants, and
for all 1,125,160 ESVs reported by ESP, ARIC, and KGP,
are shown in Figure 5A. The distributions of REVEL scores
were very similar for all reported ESVs and the subset of pu-
tatively neutral ESV training variants, with only a small
shift toward higher scores for all ESVs. Figure 5B shows
the percentiles of the REVEL scores separately for disease
and neutral training variants or all ESVs. Figure S1 shows
the sensitivity and specificity corresponding to different
REVEL score thresholds, above which a variant would be
classified as pathogenic. For example, 75.4% of disease mu-
tations but only 10.9% of neutral variants (and 12.4% of all
ESVs) have a REVEL score above 0.5, corresponding to a
sensitivity of 0.754 and specificity of 0.891. Selecting a
more stringent REVEL score threshold of 0.75 would result
in higher specificity but lower sensitivity, with 52.1% of
disease mutations, 3.3% of neutral variants, and 4.1% of
all ESVs being classified as pathogenic.6, 2016
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Figure 2. Performance of Ensemble Methods for Discrimination of Disease Training Variants from Putatively Neutral ESVs
(A) ROC curves for 6,182 HGMD disease mutations and 123,706 rare (AF 0.001–0.01) neutral ESVs used to train REVEL. REVEL scores
were computed with only the OOB predictions for its training variants.
(B) AUC for 6,182 HGMD disease mutations and 140,921 neutral ESVs, including REVEL training variants, stratified by neutral
variant AF.Discussion
REVEL is an ensemble method for predicting the pathoge-
nicity of rare missense variants. Rare variants are likely to
comprise the vast majority of variants of unknown signif-
icance discovered in future sequencing studies. We have
shown that REVEL consistently has the best overall perfor-
mance as compared to existing methods, particularly for
distinguishing disease mutations from uncommon neutral
missense variants with an AF below 3%. To facilitate use by
clinicians and researchers, we have pre-computed REVEL
scores for all missense variants in dbNSFP v2.7, a database
of all potential nonsynonymous single-nucleotide variants
in the human genome. REVEL thus addresses the need for
a pathogenicity prediction tool with improved accuracy
for interpreting rare genetic variants.
The REVEL method has several strengths. First, REVEL
was trained and tested on recently identified disease and
neutral variants that could closely resemble novel variants
discovered by future NGS studies, which are likely to
include variants with lower AFs and more modest effects
than previously discovered variants. The REVEL neutral
training variants were specifically restricted to AFs between
0.1% and 1% to improve performance when interpreting
rare variants. Second, REVEL incorporates a larger number
of individual predictors than prior ensemble methods,
including both MutPred and VEST, which were among
the most important features in the REVEL random forest.
MutPred scores, in particular, were not previously widely
available and have now been computed for all missense
variants in dbNSFP v2.7 as part of this study. Finally,
we carefully removed from the training and test sets allThe Americvariants used to train any of the component predictors in
REVEL to reduce overfitting and inflated performance
estimates.
A key limitation of this study and others is the reliance
on pathogenicity assertions from existing databases,
which might be inaccurate and incomplete. Misclassifica-
tion of training and test variants as disease or neutral
would limit both the accuracy of the prediction method
and the resulting performance estimates. Nonetheless, we
expect that the putative disease variants used to train
REVEL are enriched for true disease variants as compared
to the putative neutral variants, allowing identification
of key predictive features of pathogenic variants. An addi-
tional complication is that existing pathogenicity asser-
tions for some variants might have been based in part on
predictions from popular tools, such as SIFT and Poly-
Phen-2, potentially resulting in inflated performance of
these predictors and ensemble scores that use them.
Finally, the performance of REVEL and other ensemble
methods is limited by the accuracy of the component pre-
dictors and could benefit from inclusion of additional pre-
dictors as they become available in the future.
REVEL had the highest overall performance of any
method in independent test sets, although its performance
on common variants with AFs> 3%–5%was slightly worse
than that of MetaLR or MetaSVM. The strong overall per-
formance of REVEL reflects the fact that the majority of
neutral variants in the training and test datasets were
rare, as expected for novel variants discovered by NGS.
Furthermore, although we carefully removed all variants
used to train REVEL and its constituent features from the
two test sets, we did not systematically exclude trainingan Journal of Human Genetics 99, 877–885, October 6, 2016 881
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Figure 3. Performance of Ensemble Methods in an Independent Test Set of SwissVar Disease Mutations and Putatively Neutral ESVs
(A) ROC curves for 935 SwissVar disease mutations and 123,935 rare (AF 0.001–0.01) neutral ESVs that did not overlap with the
training set.
(B) AUC for 935 SwissVar disease mutations and 141,051 neutral ESVs, excluding REVEL training variants, stratified by neutral
variant AF.variants for the comparator ensemble scores; thus, the per-
formance estimates for the comparators could be overly
optimistic. MetaLR and MetaSVM had the next highest
overall performance. These two ensemble methods in-
cluded many of the same predictive features as REVEL,
except for VEST, MutPred, and PROVEAN, and also
included the AF, which could contribute to their greater
sensitivity to the neutral variant AF. Condel is a weighted
average of FATHMM and MutationAssessor, and its lower
performance relative to some ensemble methods couldA B
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Figure 4. Performance of EnsembleMethods in an Independent Te
(A) ROC curves and the AUC for all variants.
(B) AUC for each ensemble method, stratified by neutral variant AF.
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employs an unsupervised approach to separate variants
into two classes and also uses fewer predictive features
than REVEL, MetaLR, and MetaSVM. CADD and DANN
differ from the other ensemble methods in their use of
many basic genomic and protein annotations from
ENCODE and Ensembl as features in addition to functional
predictions from PolyPhen-2 and SIFT. Although CADD
and DANN did not perform as well as the other ensemble
methods for missense variants, they have importantREVEL
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Figure 5. Interpretation of REVEL Scores
(A) Distribution of REVEL scores for 6,182 disease (red) and 123,706 neutral (blue) training variants and 1,125,160 ESVs (black). REVEL
scores were computed with only the OOB predictions for training variants.
(B) Percentiles of the REVEL score distribution for 6,182 disease (red) and 123,706 neutral (blue) training variants and 1,125,160 ESVs
(black). REVEL scores were computed with only the OOB predictions for training variants.advantages for genome-wide NGS applications because
they provide scores for noncoding and regulatory variants
that are on the same scale as for coding variants.
The improved performance of REVEL relative to other
ensemble methods was greatest for discriminating be-
tween disease and rare neutral variants. This result might
be partly explained by the fact that REVEL was trained
on rare neutral variants with AF < 1% and did not rely
on AF as a predictive feature. To our knowledge, one other
ensemble predictor, KGGSeq,24 was similarly trained on
rare neutral variants. KGGSeq uses many of the same
component predictors as REVEL, except for MutPred, and
also includes CADD as a predictive feature. However,
KGGSeq adaptively selects an optimal subset of features
rather than using all features to predict the pathogenicity
of each variant, in part to allow exclusion of features
with missing data. Possible explanations for the improved
performance of REVEL over KGGSeq include use of all fea-
tures for all variants by first imputing missing scores,
importance of MutPred as a predictive feature, and use of
a random forest approach rather than logistic regression.
REVEL also outperformed its individual constituent pre-
diction tools, as expected for ensemble methods.19–28 The
top-performing individual tools on our training dataset
were VEST,15 FATHMM,14 and MutPred,8 consistent with
their high importance in the REVEL random forest. VEST
predictions are based on a particularly large set of 86 basic
genomic and protein annotations and had the best perfor-
mance among the individual tools. FATHMMuses a hidden
Markov modeling approach to analyze multiple sequence
alignments and alignments of conserved protein domainThe Americfamilies to compute position-specific amino acid probabili-
ties. The uniqueness of this method might contribute to
the low correlation between FATHMM and other prediction
tools and high importance in REVEL.28 Finally, the strong
performance of MutPred could be because its predictions
are based on a particularly detailed model of protein struc-
tural and functional properties, including secondary struc-
ture, solvent accessibility, functionaldomains,methylation,
phosphorylation, and glycosylation, with quantitative esti-
mates of the probability of losing each property as a result
of a particular amino acid change.
In conclusion, REVEL is an ensemble method that out-
performs existing tools for distinguishing disease variants
from rare neutral variants. REVEL can be used to prioritize
the most likely clinically or functionally relevant variants
among the sea of rare variants that are increasingly discov-
ered as sequencing studies expand in scale. For example,
REVEL scores have been used by the International
Consortium of Prostate Cancer Genetics as weights for
combining variants discovered by exome sequencing in
gene-level case-control studies. Pre-computed REVEL path-
ogenicity scores for all possible human missense variants,
based on GENCODE v9 gene annotations54 for hg19, are
available for download (see Web Resources). To aid inter-
pretation, we also provide estimates of REVEL sensitivity
and specificity for different score thresholds and the quan-
tiles of the REVEL score in over one million ESVs observed
in KGP, ESP, and ARIC. Future studies might explore the
application of REVEL to specific genes to evaluate its
clinical utility for interpreting variants of unknown signif-
icance for a broad spectrum of clinical conditions.an Journal of Human Genetics 99, 877–885, October 6, 2016 883
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